Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: A randomized, open-label, parallel-group, controlled, prospective study

Clinical Drug Investigation

Volumn 31, Issue 12, 2011, Pages 817-824

  Ciria Recasens, Manel ^a   Blanch Rubió, Josep ^a   Coll Batet, Mnica ^b   Del Pilar Lisbona Prez, Mara ^a   Dez Pérez, Adolfo ^c   Carbonell Abell, Jordi ^a   Manasanch, Jos ^d   Prez Edo, Llus ^a  

^a Rheumatology Unit   (Spain)

^b HOSPITAL DE MATARÓ   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Calcifediol; Calcium carbonate; Hydroxyapatite; Osteoporosis; Osteoporosis therapies.

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIFEDIOL; CALCIUM; CALCIUM CARBONATE; OSTEOCALCIN; PHOSPHORUS;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; COLLES FRACTURE; COLORIMETRY; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; HUMERUS FRACTURE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENILE OSTEOPOROSIS; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFEDIOL; CALCIUM CARBONATE; DIETARY SUPPLEMENTS; DURAPATITE; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; PROSPECTIVE STUDIES; VITAMINS;

EID: 80155146578     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11592930-000000000-00000     Document Type: Article

References (29)

1. Melton LJ. How many women have osteoporosis now?. J Bone Miner Res 1995; 10: 175-7
2. Diez A, Puig J, Martinez MT, et al. Epidemiology of fractures of the proximal femur associated with osteoporosis in Barcelona, Spain. Calcif Tissue Int 1989; 44: 382-6 (Pubitemid 19146907)
3. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8 (Pubitemid 34925651)
4. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis: a review of the literature and a reference model. Osteoporos Int 2007; 18: 9-23 (Pubitemid 44885492)
5. Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-86 (Pubitemid 16097845)
6. Marshall D, Johnell O, Wedel H.Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9 (Pubitemid 26147662)
7. Schott AM, Cormier C, Hans D, et al. How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study. Osteoporos Int 1998; 8: 247-54 (Pubitemid 28427074)
8. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk?. J Bone Miner Res 2000; 15: 183-7 (Pubitemid 30095704)
9. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-92 (Pubitemid 34615244)
10. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004; 34: 599-604 (Pubitemid 38393794)
11. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996; 18: 141-50 (Pubitemid 26092594)
12. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40 (Pubitemid 32107641)
13. Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure. Arch Intern Med 2006; 166: 869-75
14. Cumming R, Cumming S, Nevitt M. Calcium intake and fracture risk: results from the study of osteoporotic fractures. Am J Epidemiol 1997; 145: 927-35
15. Shea B, Wells G, Cranney A, et al. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002; 23: 552-9 (Pubitemid 34925649)
16. Shea B,Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004; (1): CD004526
17. Felsenberg D, Boonen S. The Bone Quality Framework: determinants of bone strength and their interrelationship, and implications for osteoporosis management. Clin Ther 2005; 27: 1-11 (Pubitemid 40342573)
18. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010 [online]. Available from URL: http://www.nof.org/professionals/ clinical-guidelines [Accessed 2011 Aug 1]
19. Annefeld M, Caviezel R, Schacht E, et al. The influence of ossein-hydroxyapatite compound on the healing of a bone defect. Curr Med Res Opin 1986; 10: 241-50 (Pubitemid 16021301)
20. Schmidt KH, Wö rner VM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 1988; 11: 107-15
21. Chavassieux P, Pastoreau P, Boivin G, et al. Effects of ossein-hydroxyapatite compound on ewe bone remodelling: biochemical and histomorphometric study. Clin Rheumatol 1991; 10: 269-73
22. Castelo-Branco C, Vicente JJ, Haya J. Complejo de oseí nahidroxiapatita. In: Castelo-Branco C, Haya Palazuelos J, editors. Osteoporosis y menopausia. Madrid: Editorial Médica Panamericana, 2004: 357-64
23. Ruegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporos Int 1995; 5: 30-4
24. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-48 (Pubitemid 23261108)
25. Castelo-Branco C, Pons F, Vicente JJ, et al. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds: results of a two-year, prospective trial. J Reprod Med 1999; 44: 601-5 (Pubitemid 29350456)
26. Pelayo I, Haya J, De la Cruz JJ, et al. Raloxifene plus osseinhydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause 2008; 15: 1132-8
27. Castelo-Branco C, Ciria-Recasens M, Cancelo-Hidalgo MJ, et al. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a metaanalysis. Menopause 2009; 16: 984-91
28. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; 11: 2-17
29. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess 2007; 158: 1-235